AR022791A1 - Composiciones y metodos para el tratamiento de la infeccion por estafilococo mientras que suprimen la formacion de cepas resistentes al antibiotico - Google Patents

Composiciones y metodos para el tratamiento de la infeccion por estafilococo mientras que suprimen la formacion de cepas resistentes al antibiotico

Info

Publication number
AR022791A1
AR022791A1 ARP000100885A ARP000100885A AR022791A1 AR 022791 A1 AR022791 A1 AR 022791A1 AR P000100885 A ARP000100885 A AR P000100885A AR P000100885 A ARP000100885 A AR P000100885A AR 022791 A1 AR022791 A1 AR 022791A1
Authority
AR
Argentina
Prior art keywords
antibiotic
resistant
infection
cell wall
staphilococo
Prior art date
Application number
ARP000100885A
Other languages
English (en)
Original Assignee
Ambi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambi Inc filed Critical Ambi Inc
Publication of AR022791A1 publication Critical patent/AR022791A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La co-administracion de una lisostafina u otro agente anti-estafilococo que desdobla los entrecruzamientos de peptidoglicanos de las paredes celulares deestafilococo como por ejemplo, lisostafina y un antibiotico efectivo contra los estafilococosdeb ido a la actividad antibiotica mediada por medio de la paredcelular es efectiva contra la infeccion por estafilococo, incluso estafilococos que pueden ser resistentes a una u otra lisostafina o antibiotico activo enpared celular. La co-administracion simultánea suprime la generacion de las cepas mutantes resistentes al antibiotico. Los antibioticos activos en la paredcelular efectivos, incluyen a las beta-lactamas y glicopéptidos.
ARP000100885A 1999-03-05 2000-02-29 Composiciones y metodos para el tratamiento de la infeccion por estafilococo mientras que suprimen la formacion de cepas resistentes al antibiotico AR022791A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/263,776 US6569830B1 (en) 1999-03-05 1999-03-05 Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains

Publications (1)

Publication Number Publication Date
AR022791A1 true AR022791A1 (es) 2002-09-04

Family

ID=23003182

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100885A AR022791A1 (es) 1999-03-05 2000-02-29 Composiciones y metodos para el tratamiento de la infeccion por estafilococo mientras que suprimen la formacion de cepas resistentes al antibiotico

Country Status (14)

Country Link
US (4) US6569830B1 (es)
EP (1) EP1181011A4 (es)
JP (1) JP2002538108A (es)
KR (1) KR20020010893A (es)
CN (1) CN1353602A (es)
AR (1) AR022791A1 (es)
AU (1) AU780864B2 (es)
BR (1) BR0008779A (es)
CA (1) CA2362487A1 (es)
IL (1) IL145282A0 (es)
NO (1) NO20014314L (es)
PL (1) PL364875A1 (es)
WO (1) WO2000051588A1 (es)
ZA (1) ZA200108215B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
JP2006514636A (ja) * 2002-12-02 2006-05-11 バイオシネクサス インコーポレーテッド 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸
US7166634B2 (en) * 2004-01-23 2007-01-23 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobials agents
US7522663B2 (en) * 2005-03-10 2009-04-21 Stmicroelectronics, Inc. Burst error limiting feedback equalizer system and method for multidimensional modulation systems
WO2007008618A2 (en) * 2005-07-13 2007-01-18 University Of South Carolina Sterilization using high-pressure carbon dioxide
GB0600928D0 (en) * 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
US20090082344A1 (en) * 2006-07-13 2009-03-26 Searete Llc Methods and systems for treating disease
US20080015834A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition
US20080015833A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition of protein misfolding
US20080014572A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition
GB0714029D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009152298A1 (en) * 2008-06-13 2009-12-17 Zeus Scientific, Inc. Methods, compositions and and diagnostic kits for the detection and treatment for staphylococcal nasal decolonization using achromopeptidase
RS53586B1 (en) 2009-01-14 2015-02-27 Novacta Biosystems Limited DERIVATION OF DECISION
SG173504A1 (en) 2009-02-04 2011-09-29 Novacta Biosystems Ltd Actagardine derivatives
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
JP2015536949A (ja) * 2012-11-01 2015-12-24 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 細菌感染症のための抗生物質を用いる方法および組成物
EP3096778A2 (en) * 2013-12-28 2016-11-30 Staphrx, Llc Ultra-low dose lysostaphin for treating mrsa
EP3143137A4 (en) 2014-05-14 2017-11-15 Trustees of Dartmouth College Deimmunized lysostaphin and methods of use
SG11201914046WA (en) 2017-07-07 2020-01-30 Epicentrx Inc Compositions for parenteral administration of therapeutic agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278378A (en) 1962-04-19 1966-10-11 Schindler Charles Alvin Staphylococcus-derived antibiotic
US3398056A (en) 1964-07-10 1968-08-20 Mead Johnson & Co Process for producing lysostaphin by fermentation
US3594284A (en) 1968-06-04 1971-07-20 Mead Johnson & Co Lysostaphin fermentation with accelerated time cycle
US4931390A (en) 1986-04-16 1990-06-05 Public Health Research Institute Of The City Of New York, Inc. Expression of the cloned lysostaphin gene
US5858962A (en) 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
AU623864B2 (en) 1988-08-29 1992-05-28 Applied Microbiology, Inc Method of treating mastitis and other staphylococcal infections
JPH0645553B2 (ja) * 1988-09-19 1994-06-15 アプライド マイクロバイオロジィ，インコーポレイテッド 乳房炎およびその他のブドウ球菌感染症の治療法並びに同治療用組成物
US5466685A (en) 1993-05-13 1995-11-14 Johnson & Johnson Inhibition of expression of beta-lactamase using esters of fatty acid alcohols
US6028051A (en) 1997-07-23 2000-02-22 Ambi Inc. Method for the treatment of staphylococcal disease
NZ502359A (en) * 1997-07-23 2005-02-25 Ambi Inc Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains

Also Published As

Publication number Publication date
AU780864B2 (en) 2005-04-21
KR20020010893A (ko) 2002-02-06
CN1353602A (zh) 2002-06-12
US20030199432A1 (en) 2003-10-23
NO20014314L (no) 2001-10-11
EP1181011A4 (en) 2003-05-21
US8198231B2 (en) 2012-06-12
IL145282A0 (en) 2002-06-30
EP1181011A1 (en) 2002-02-27
US7122514B2 (en) 2006-10-17
US6569830B1 (en) 2003-05-27
JP2002538108A (ja) 2002-11-12
CA2362487A1 (en) 2000-09-08
US20060246055A1 (en) 2006-11-02
AU3249000A (en) 2000-09-21
NO20014314D0 (no) 2001-09-05
US7078377B1 (en) 2006-07-18
PL364875A1 (en) 2004-12-27
BR0008779A (pt) 2002-10-15
WO2000051588A1 (en) 2000-09-08
ZA200108215B (en) 2006-03-29

Similar Documents

Publication Publication Date Title
AR022791A1 (es) Composiciones y metodos para el tratamiento de la infeccion por estafilococo mientras que suprimen la formacion de cepas resistentes al antibiotico
EA200000594A1 (ru) Новые макролиды
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
AU2742401A (en) Methods and compositions for improved delivery devices
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
AR031135A1 (es) Composiciones de antibiotico topico para el tratamiento de infecciones oculares
BR0112750A (pt) Aminopiperidina quinolinas e seus análogos azaisostéricos com atividade antibacteriana
UY26391A1 (es) Inhibidores sglt2 de glucosidos de c-arilo y metodo
DE69713148D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
ES2159591T3 (es) Composicion de liberacion controlada.
DE69713152D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
BR9714287A (pt) Antibiótico cristalino designado solvato 6-o-metileritromicina forma 0, solvato de 6-o-metileritromicina forma 0, composição, processos para tratamento de infecções bacterianas em um mamìfero hospedeiro com necessidade de tal tratamento e para preparação de solvato de 6-o-metileritomicina a forma 0, 6-o-metileritromicina forma 0--etanolato, suspensão para administração oral, e, complexo de solvato de 6-o-metileritromicina a forma 0-carbÈmero.
ES2065471T3 (es) Composiciones acuosas antibacterianas que comprenden un tensoactivo y bacteriofagos.
ES2085268T3 (es) Composicion detergente enzimatica.
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
AR058795A1 (es) Metodo para inhibir las enzimas beta-lactamasas de clase d en el tratamiento de infeccion bacteriana en un paciente
BR112022010891A2 (pt) Combinação de um antagonista do receptor lpa1 de azetidina com agentes antifibróticos
BRPI0413964B8 (pt) ácido derivado do ácido carboxílico quinolona, sua composição e agente antibacterial
BR0011225A (pt) Agente para tratar de olhos secos, seu método e uso
DE69430385D1 (de) Hiv-proteaseinhibitoren
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
AR029544A1 (es) Composiciones y metodos para tratar infecciones bacterianas
RS82504A (en) Isostructural pseudopolymorphs of 9- deoxo-9a-aza-9a-methil- 9a- homoerythromycin a
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.

Legal Events

Date Code Title Description
FB Suspension of granting procedure